NER1006 (Plenvu)

Other Medications · Approved since 2018

US FDA Approved Oral 3 Clinical Trials

Description

NER1006 is a low-volume polyethylene glycol (PEG)-based bowel cleansing solution specifically formulated for colorectal preparation prior to colonoscopy and colorectal cancer screening procedures. This medication is designed as a split-dose regimen that provides effective bowel cleansing with improved patient tolerability compared to traditional high-volume preparations. NER1006 plays a critical role in colorectal cancer diagnosis and surveillance by ensuring optimal bowel preparation for accurate visualization during colonoscopic examination.

Mechanism of Action

NER1006 contains polyethylene glycol 3350 combined with electrolytes that work through osmotic action to retain water in the intestinal lumen, promoting bowel evacuation. The formulation creates an osmotic gradient that prevents significant fluid and electrolyte absorption, leading to comprehensive cleansing of the colon while maintaining electrolyte balance.

Side Effects

Nausea Abdominal distension Abdominal pain Vomiting Anal discomfort Thirst Malaise Dehydration

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02254486 Phase 3
Archived
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
United States
NCT01714466 Phase 2
Archived
Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy
Germany
NCT01834742 Phase 1
Archived
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects
Romania

Quick Info

Brand NamePlenvu
CategoryOther Medications
US StatusFDA Approved
AdministrationOral
Year Approved2018
Clinical Trials3
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.